Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Zylox Tonbridge (2190 HK): Optimed Acquisition Is a Positive Step Forward Towards Future Growth

Zylox Tonbridge Medical (2190 HK): No More Interventions Needed, Blockages Cleared for Growth

Zylox Tonbridge (2190 HK): 2025 Good; International Presence, Product Launches Will Shape the Future

Equity Bottom-Up

Zylox-Tonbridge Medical Technology / Equity Bottom-Up

Zylox-Tonbridge Medical Technology (2190 HK)

<ul>
<li>Zylox Tonbridge Medical (2190 HK) achieved a revenue of RMB 632M, up 31% YoY, primarily attributable to the high sales growth of both neurovascular and peripheral vascular interventional devices segments. </li>
<li>In 1H26, Zylox achieved success in international business with a revenue of RMB 70.6M, up 349%, primarily from Europe, Asian and Latin American regions.</li>
<li>The global growth prospects will provide the required positive impetus going forward. We feel the stock has ample room for growth and value appreciation left within.</li>
</ul>


Zylox Tonbridge Medical (2190 HK) achieved a revenue of RMB 632M, up 31% YoY, primarily attributable to the high sales growth of both neurovascular and peripheral vascular interventional devices segments. 
In 1H26, Zylox achieved success in international business with a revenue of RMB 70.6M, up 349%, primarily from Europe, Asian and Latin American regions.
The global growth prospects will provide the required positive impetus going forward. We feel the stock has ample room for growth and value appreciation left within.


Zylox Tonbridge (2190 HK): Domestic Holds, International Stellar in 1H26, Pipeline and Launches Key